Diagnostic Value and Safety of Stereotactic Biopsy for Brainstem Tumors
- 1 June 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurosurgery
- Vol. 72 (6), 873-882
- https://doi.org/10.1227/neu.0b013e31828bf445
Abstract
BACKGROUND: The feasibility and safety of stereotactic biopsy for brainstem tumors (BSTs) are controversial. Although magnetic resonance imaging (MRI) has been reported as the preferred diagnostic tool, histopathological analysis is frequently necessary to establish a definitive diagnosis. Recent advances in molecular characterization of brainstem gliomas-accounting for the majority of BSTs-have revealed several potential targets for molecular-based therapies. Hence, a molecular stereotactic biopsy that combines histopathological diagnosis with molecular-genetic analysis will become increasingly important for patients with BSTs. OBJECTIVE: We conducted a systemic review and meta-analysis to determine the risks and benefits of stereotactic biopsy for BSTs. METHODS: A systematic search in PubMed, Embase, and the Web of Science yielded 3766 potentially eligible abstracts. Meta-analysis was conducted on 38 studies describing 1480 biopsy procedures for BSTs. Primary outcome measures were diagnostic success and procedure-related complications. Data were analyzed according to standard meta-analytic techniques. RESULTS: The weighted average proportions across the analyzed studies were: 96.2% (95% confidence interval [CI]: 94.5%-97.6%) for diagnostic success, 7.8% (95% CI: 5.6%-10.2%) for overall morbidity, 1.7% (95% CI: 0.9%-2.7%) for permanent morbidity, and 0.9% (95% CI: 0.5%-1.4%) for mortality. Meta-regression revealed a significant correlation between diagnostic success rates and the number of biopsy procedures performed annually in each center (P = .011). Other factors did not affect the outcome measures. CONCLUSION: Stereotactic biopsy of BSTs is safe. It allows exact histopathological diagnosis as a prerequisite for adequate treatment and opens new perspectives for the molecular characterization of these tumors as a crucial first step toward more individualized treatment concepts.Keywords
This publication has 40 references indexed in Scilit:
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Diffuse intrinsic pontine gliomas: New wavesNeuro-Oncology, 2012
- Correlation between magnetic resonance imaging findings and histological diagnosis of intrinsic brainstem lesions in adultsNeuro-Oncology, 2012
- Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine GliomaJournal of Clinical Oncology, 2011
- Stereotactic robot-guided biopsies of brain stem lesions: Experience with 15 casesNeurochirurgie, 2010
- Transcerebellar stereotactic biopsy for brainstem lesions in childrenJournal of Pediatric Neurosciences, 2009
- Brainstem gliomas in children and adultsCurrent Opinion in Oncology, 2008
- Stereotactic biopsy of brain stem masses: decision analysis and literature reviewSurgical Neurology, 2006
- Stereotactic biopsies of focal brainstem lesionsSurgical Neurology, 2003
- Stereotactic biopsy of brainstem mass lesionsSurgical Neurology, 1995